Table 2.
Distribution of the number of head and neck tumours in patients who underwent radiotherapy at the Hospital of UOPECCAN (n = 55)
| Characteristics | Frequency | % |
|---|---|---|
| Primary tumour site | ||
| Mouth | 14 | 25.5 |
| Oropharynx | 17 | 30.9 |
| Larynx | 16 | 29.1 |
| Hypopharynx | 2 | 3.6 |
| Salivary glands | 5 | 9.1 |
| Unknown | 1 | 1.8 |
| Tumour size (TNMa) | ||
| T1 | 8 | 14.5 |
| T2 | 10 | 18.2 |
| T3 | 10 | 18.2 |
| T4 | 17 | 30.9 |
| T4a | 5 | 9.1 |
| Not informed | 5 | 9.1 |
| Lymph node involvement (TNMa) | ||
| N0 | 25 | 45.5 |
| N1 | 14 | 25.5 |
| N2a | 10 | 18.2 |
| N2b | 2 | 3.6 |
| N3 | 3 | 5.5 |
| Not informed | 1 | 1.8 |
| Clinical stage | ||
| I | 3 | 5.5 |
| II | 8 | 14.5 |
| III | 17 | 30.9 |
| IV | 20 | 36.4 |
| IVa | 7 | 12.7 |
| Histopathological diagnosis | ||
| Squamous cell carcinoma | 47 | 85.5 |
| Others | 8 | 14.5 |
| Oncological treatment | ||
| Radiotherapy | 5 | 9.1 |
| Radiotherapy and surgery | 18 | 32.7 |
| Radiotherapy and chemotherapy | 18 | 32.7 |
| Radiotherapy, surgery, and chemotherapy | 14 | 25.5 |
| Post-treatment period (months) | ||
| 8 - 18 | 16 | 29.1 |
| 19 - 36 | 19 | 34.5 |
| 37 - 54 | 11 | 20 |
| 55 - 72 | 9 | 16.4 |
| Dose (Gy) | ||
| ≥ 22 < 50.5 | 4 | 7.3 |
| ≥ 50.5 < 64 | 20 | 36.4 |
| ≥ 64 ≤ 70.2 | 31 | 56.4 |
aTNM, as proposed by the International Union against Cancer (UICC). Source: https://www.uicc.org/resources/tnm
T4a = Tumours in advanced stages invading adjacent anatomical structures, depending on the tumour origin.
N2a = Single regional lymph node involved, ipsilateral to the tumour.
N2b = Multiple regional lymph nodes involved, ipsilateral to the tumour.
IVa = T4a, N0 or N1, M0 or, T1 to T4a, N2, M0.